The Celltex Affair
By Carl Elliott,
Slate
| 02. 17. 2012
The stem-cell tourism industry is not exactly renowned for ethical probity, much less scientific rigor. Given its reputation for peddling untested remedies to desperate patients, not to mention its starring role in several sting operations on 60 Minutes, a few eyebrows went up when one of the nation's leading journals of medical ethics relocated to the offices of a commercial stem cell clinic in Sugar Land, Texas. In December, the editor of the American Journal of Bioethics, a man called Glenn McGee, took up a new job with Celltex Therapeutics as its president for ethics and strategic initiatives. He now works for a new business venture that is partnered with a shady South Korean company known for its commercial puppy-cloning ventures, and co-founded by the surgeon who made headlines last year by treating Rick Perry's back pain with unapproved adult stem cells. Some bioethicists are defending the move, suggesting that any potential conflicts of interest can be managed, but they have failed to appreciate the extent of McGee's questionable history with stem cell tourism—in particular, his...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...